tbuckley/cabot-search huggingface dataset:
Abstract 3464: Gender Differences In Coronary Revascularization Rates Following Acute Myocardial Infarction
Authors: Tara Sedlak, Aihua Pu, Eve Aymong, Min Gao, Nadia Khan, Hude Quan, Karin Humphries
Journal: Circulation (2007)

Objective(s): Studies suggest that early revascularization following an AMI is equally important in both genders. We examined coronary revascularization (PCI or CABG) rates in men and women following an AMI. Methods: We studied a cohort of 7 728 patients &gt;20 years with an AMI admission between January 1, 1999, and September 30, 2002 who underwent catheterization within 90 days of their index AMI. Demographic, clinical, and procedural data were obtained from the British Columbia (BC) Cardiac Registry, a prospective registry of all cardiac procedures performed in BC. Patients without 180 days of available follow-up and patients with a normal angiogram were excluded. Our primary objective was to examine gender differences in the odds of undergoing coronary revascularization within 180 days of the index coronary catheterization. We also examined time trends in revascularization rates by gender from 1999 to 2002. Results: Of the 6 726 eligible patients, 68.2% of women and 78.4% of men underwent revascularization within 180 days of their index catheterization following an AMI (p&lt;0.0001). After adjusting for age, extent of vessel disease, hyperlipidemia, LVEF, DM, CHF, CRF, HTN, PVD, CVA, COPD, liver disease, cancer, case complexity, ICU/CCU use, and catheterization year, women were still less likely to undergo revascularization (OR 0.80, 95% CI 0.70 – 0.93). There was no interaction between gender and year of catheterization post-AMI (Figure 1 ). Conclusion: Conditional on receiving coronary catheterization within 90 days following an AMI, women were less likely to undergo coronary revascularization within 180 days compared to men. The gender difference persisted from 1999 to 2002.
A CASE OF PANCREATIC LITHIASIS
Authors: D. B. Faust, W. G. Brandstadt
Journal: Annals of Internal Medicine (1942)

Case Reports1 July 1942A CASE OF PANCREATIC LITHIASISD. B. FAUST, M.D., F.A.C.P., W. G. BRANDSTADT, M.D.D. B. FAUST, M.D., F.A.C.P.Search for more papers by this author, W. G. BRANDSTADT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-17-1-148 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough some 113 or more cases of pancreatic lithiasis have been reported, it is still rarely diagnosed during life. In 1937 Höchstetter1was able to find only four cases diagnosed by roentgen-ray before operation and 30 diagnosed on the operating table. The rest of the reported cases have been revealed only at autopsy. Since the symptoms produced are variable and quite unreliable, and since the stones found in the pancreas are ray-opaque, the roentgen-ray is our most valuable means of diagnosis in this condition. As was pointed out by one of us (D. B. F.) in 1935,2it is necessary...References1. HÖCHSTETTER S: Pancreatic lithiasis, Am. Jr. Roentgenol., 1937, xxxvii, 33-35. Google Scholar2. FAUST DB: Pancreatic lithiasis, ANN. INT. MED., 1935, ix, 625-637. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Washington, D. C.*Received for publication November 14, 1939.†Walter Reed General Hospital, Washington, D. C. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byComparative Study of Cystic Fibrosis of the Pancreas and Chronic Calcareous Pancreatitis; Three Case Reports of Calcareous Pancreatitis 1 July 1942Volume 17, Issue 1Page: 148-152KeywordsAutopsyPancreas Issue Published: 1 July 1942 PDF downloadLoading ...
Antibiotics carried in general practitioners' emergency bags
Authors: S W S Menzies
Journal: BMJ (1995)

and a defibrillator as well as my medical bag up five flights of stairs in a block of flats, where the lift is invariably out of order or its floor swimming in urine?What do I do with the equipment while visiting patients who do not require it?If I leave it in the car the possibility of its being stolen is high.Have the authors considered the practical implications of their advice?
Toxicity of concurrent radiotherapy with CMF chemotherapy in the E-CMF adjuvant breast carcinoma regimen
Authors: D. N. Church, M. Flubacher, A. Cameron, A. Bahl, J. Braybrooke
Journal: Journal of Clinical Oncology (2007)

582 Background: In the adjuvant management of breast cancer although delivery of radiotherapy (RT) concurrently with anthracyclines is contraindicated, toxicities are acceptable when the chemotherapy regimen used is CMF. The NEAT trial (NEJM 2006; 355:1851- 1862), presented at ASCO in 2003 demonstrated a significant survival advantage for sequential 4x epirubicin and 4x CMF chemotherapy (E- CMF) compared with 6x CMF and was adopted in the UK as a standard regimen. In order to limit treatment duration, RT may be given concurrently with chemotherapy during the CMF phase of treatment. We have reviewed the toxicity associated with this approach. Methods: Retrospective review of all patients treated with concurrent breast RT and CMF chemotherapy as part of the E-CMF regimen in our institution. Toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) toxicity criteria. Confidence intervals were calculated by the binomial method using Stata version 9. Results: 77 patients received concurrent therapy between March 2004 and May 2006. Baseline characteristics; median age: 48, ER positive: 63.5%, HER2 positive: 11.7%, node positive disease: 85.7%. Type of surgery; lumpectomy: 61.0%, mastectomy: 39.0%, nodal dissection: 100%. Chemotherapy delivery; completed without delay: 35.1%, completed therapy with dose reduction/delay: 48.1%, discontinued therapy prematurely due to toxicity 16.8%. Sites of RT; breast: 62.3%, chest wall: 35.1%, axillary nodes: 45.5%, supraclavicular fossa: 36.4%. Schedule of RT; 50Gy/25#: 18.2%, 46/45Gy/20#: 67.6%, 45Gy/15#: 14.3%. Median interval between final dose of epirubicin and start of RT: 55 days. Toxicity; cutaneous grade 3–4 acute radiotherapy toxicity: 31.2% (95%CI 21.1–42.7%); cutaneous infective cellulitis: 14.3% (95%CI 7.4–21.1%); grade 3–4 neutropenia: 54.4% (95%CI 42.8–65.9%); febrile neutropenia requiring hospitalisation: 22.1% (95% CI 13.4–33.0%). The median duration of stay in hospitalised patients was 8 days (range 3–23 days). Conclusions: Toxicities were significantly greater than documented previously for concurrent therapy. RT should not be given concurrently with CMF chemotherapy as part of the E-CMF regimen. No significant financial relationships to disclose.
Twentieth Century Painting
Authors: John Sandberg
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group
Authors: J. Gilbert, J. Lee, A. Argiris, L. Feldman, M. Haigentz, B. Burtness, A. Forastiere
Journal: Journal of Clinical Oncology (2009)

6020 Background: B, inhibits activation of NF- κβ and inhibits growth of SCCHN cell lines. NF-κβ dysregulation contributes to chemoresistance, including I. Pretreatment with B increases tumor sensitivity to I in vitro. Methods: Eligibility: 0–1 prior chemo regimens, ECOG PS 0–1. Pts randomized to B 1.3 mg/m2 IV d 1, 4, 8, 11 and I 125 mg/m2 IV d 1, 8 every 21 days (Arm 1) or B with addition of I at time of progression (Arm 2). Primary endpoint was response rate (RR) using RECIST and Simon's optimal 2-stage design. Results: 62 pts analyzable (Arm 1, N = 23; Arm 2, N = 39) of 71 enrolled . Pt. characteristics: median age 61 yrs., ECOG PS 1 - 53 %, and 71% had prior chemo. To date, RR (all PRs) 13% Arm 1 and 3% Arm 2 with SD 17% Arm 1 and 23% Arm 2. However, 3 patients remain on active therapy in Arm 2 and PFS and updated RR will be reported. 7 patients (including 3 pts on Arm 2) received 6–10 cycles of therapy. No responses in all 11 analyzable pts in Arm 2 with I added at progression. Median OS 9.1 months - Arm 1 and 7.3 months - Arm 2. Toxicity of B + I (125 mg/m2): grade 3/ 4 neutropenia (31%), vomiting (15%), diarrhea (15%), dehydration (23%). Grade 5 toxicity in 3 pts, 2 possibly related to therapy. Trial amended to decrease I to 90 mg/m2 3 patients (33%) - grade 3 / 4 diarrhea; no grade 3/ 4 neutropenia or grade 5 toxicities. Arm 2: grade 3 / 4 fatigue (15%). Conclusions: B alone is well tolerated. To date, RR low but prolonged stable disease noted in some pts. B in combination with I is a toxic regimen with disappointing activity. [Table: see text]
Evidence for the delayed effect in human ischemic preconditioning
Authors: Toshiyuki Noda, Shinya Minatoguchi, Kenshi Fujii, Masatsugu Hori, Takayuki Ito, Katsuo Kanmatsuse, Masunori Matsuzaki, Tetsuji Miura, Hiroshi Nonogi, Michihiko Tada, Masaru Tanaka, Hisayoshi Fujiwara
Journal: Journal of the American College of Cardiology (1999)
Intrinsic Mutagenesis: A Genetic Approach to Ageing.
Authors: Frank Macfarlane Burnet
Journal: Annals of Internal Medicine (1975)

This book is something which almost accidentally has developed very differently from how it was initially planned. The intention was to elaborate the part played by the immune system in ageing with the role of the thymus as central theme. It was to be essentially an expansion of a lecture I gave in 1970 and would inevitably have been concerned with much the same material as Walford's book, The Immunologic Theory of Aging, though from a different slant. What changed its character arose from a series of attempts to find logical connection between two findings that most gerontologists regard as axiomatic: that the lifespan of a mammal is genetically determined, and that the actual process of ageing is an accumulation of genetic error, of somatic mutations. It is possible that the connection is so indirect, circuitous and multiform that generations of detailed and unattractive research will be needed to elucidate it, or, more likely, the whole matter discarded as a non-problem. But a more inspiring approach does seem possible. The working hypothesis, which halfway through its writing became the new central theme of the book, arose when I was a member of a committee appointed by the Australian Academy of Science at the request of the Australian Government to advise on the danger from French nuclear tests in the South Pacific.
Abstract 11493: Gene Therapy with BRCA1 Reduces Systemic Inflammatory Response and Multiple Organ Failure and Improves Survival in Experimental Sepsis
Authors: Hwee Teoh, Adrian Quan, Amie Creighton, KW Annie Bang, Praphulla Shukla, Krishna Singh, Nandini Gupta, Yi Pan, Fina Lovren, Howard Leong-Poi, Mohammed Al-Omran, Subodh Verma
Journal: Circulation (2011)

Sepsis-related complications and mortality remain a major clinical problem in critically ill cardiothoracic patients. Increased activation of cell death pathways and unresolved DNA repair have been...
Federal Food, Drug, and Cosmetic Act: Judicial and Administrative Record 1949-1950
Authors: Vincent A. Kleinfeld, Alan H. Kaplan
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 17334: Stress Provokes Endothelial Dysfunction and Insulin Resistance Partly Through Activation of NF-kB and Inhibition of Insulin Signaling Pathway to NO Production by Corticotropin-releasing Hormone
Authors: Ick-Mo Chung, Hee Young Kim, Youn Jung Lee, Young Mi Park, Yejin Ha, Youngmi Lee
Journal: Circulation (2013)

Background: Psychological stress probably contributes to development of atherosclerosis and insulin resistance. However, its underlying mechanism is poorly understood. We studied if stress induces ...
The Indications for and the Results of the Use of Novasurol, With Reports of Seven Cases
Authors: H. M. Andison
Journal: Annals of Internal Medicine (1927)

Article1 July 1927The Indications for and the Results of the Use of Novasurol, With Reports of Seven CasesH. M. ANDISONH. M. ANDISONSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-1-1-33 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe value of novasurol as a diuretic of hitherto unprecedented efficiency has come to be recogized during the past seven years. The first account of its use as a diuretic was given by Saxl and Heilig in 1920 and since that time the fact that this drug can overcome edema which has resisted the usual forms of medication has been confirmed by many observers. When used alone it is capable of increasing the output of urine in a most striking manner; but we have found, as have others, that its effect is strikingly enhanced by giving ammonium chlorid at the...References OERTING H: Use of novasurol as diuretic, Minnesota Med., 1925, viii, 593-596. Google Scholar CRAWFORDMCINTOSH JHJT: Use of novasurol in edema due to heart failure, J. Clin. Investigation, 1925, i, 333-358. CrossrefGoogle Scholar KEITHBARRIERWHELAN NMCWM: The diuretic action of ammonium chlorid and novasurol in cases of nephritis with edema, Jr., Am. Med. Ass., 1925, lxxxv, 799-806. CrossrefGoogle Scholar ROWNTREEKEITHBARRIER LGNMCW: Novasurol in treatment of ascites in hepatic disease, Jr. Am. Med. Ass., 1925, lxxxv, 1187-1193. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cleveland Clinic Cleveland, Ohio*Clinical discussion given before the American College of Physicians at the Cleveland Clinic, February 22-25, 1927. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1927Volume 1, Issue 1Page: 33-38KeywordsDiureticsDrugsEdemaUrine ePublished: 1 December 2008 Issue Published: 1 July 1927 PDF downloadLoading ...
Chemistry of the Opium Alkaloids.
Authors: Lyndon F.Small, Robert E. Lutz
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nursing is underrepresented
Authors: J. Robinson, A. M. Rafferty
Journal: BMJ (1995)

EDITOR,—Fiona Godlee's controversial articles on the World Health Organisation expose its strengths and weaknesses but make scant mention of the contribution of nursing to its operations and organisation.1 This is particularly regrettable given the articles' attention to the medical dominance of the organisation. We can conclude only that the absence of any substantive discussion of nursing reflects the perceived invisibility of nursing within the organisation more generally.

A recent study of nurses in government and …
Abstract 1490: The Nitric Oxide (NO) Donor Molsidomine Rescues Heart Function in Experimental Cardiorenal Failure
Authors: Lennart G Bongartz, Branko Braam, Marianne C Verhaar, Maarten Jan M Cramer, Roel Goldschmeding, Carlo A Gaillard, Pieter A Doevendans, Jaap A Joles
Journal: Circulation (2008)
Investigating the predictive value of topoisomerase II alpha (TOP2A) gene, mRNA and protein levels in anthracycline-treated estrogen receptor (ER) negative breast cancer (BC) patients
Authors: C. Desmedt, E. Azambuja, D. Larsimont, S. Delaloge, C. Duhem, G. Rouas, A. Di Leo, V. D’Hondt, M. Piccart, C. Sotiriou
Journal: Journal of Clinical Oncology (2008)

11065 Background: Anthracycline-based regimens are among the most active chemotherapies in BC. However, their clinical use is associated with rare but significant toxicities and their efficacy remains concentrated on a subset of BC patients. TOP2A, the molecular target of anthracyclines, has repeatedly been suggested to be a potential marker of response to this therapy. Here we aimed to investigate: 1/ the correlation between the gene, mRNA and protein levels of TOP2A; 2/ the genes differentially expressed between TOP2A amplified and normal tumors; and 3/ the predictive value of TOP2A gene, mRNA and protein levels, in a prospective neoadjuvant trial designed primarily to identify markers of response to epirubicine in ER-negative patients (to eliminate the confounding effect of indirect ovarian suppression in ER+ BC). Methods: We analyzed TOP2A at the gene level using fluorescence in situ hybridization (Vysis triple probe), at the mRNA level using Affymetrix and at the protein level by immunohistochemistry (KiS1) in a series of 121 samples. Results: 1/ We observed a correlation between the mRNA levels and the FISH ratios (rho=0.37, p=0.007), but no correlation between the mRNA and IHC levels. 2/ 10% of the samples showed TOP2A amplification. We identified a list of genes differentially expressed between TOP2A amplified and non-amplified tumors. A large number of these genes were located on the TOP2A amplicon, such as RARA, CDC6, WIRE, 3/15% of the patients had a pathological complete response. TOP2A amplification, which was exclusively observed in HER2 amplified cases (=32% of them), was predictive of response (kappa= 0.44, p=0.01). 61% of the samples overexpressed TOP2A (>10% of positively stained cells) but these protein levels, as well as the mRNA levels were not predictive of response. Conclusions: This study, which is the first to evaluate the predictive value of TOP2A in patients treated by epirubicin single-agent, shed light on the genes differentially expressed by TOP2A amplified tumors and suggests TOP2A gene levels, but not mRNA and protein levels, to be associated with response to anthracyclines. Since the trial is ongoing, these results will be validated on the next series of patients. No significant financial relationships to disclose.
Abstract 5493: Heparan-Sulfate Deficient Perlecan Mice Exhibit Increased Vascular Smooth Muscle Cell Activity and Response to Arterial Injury
Authors: Lara Gotha, Parween Abdulla, Julia Lockwood, Bradley Strauss
Journal: Circulation (2008)

Percutaneous coronary interventions (PCI) are limited by restenosis, a process that involves smooth muscle cell (SMC) proliferation and migration. Perlecan, a heparan-sulfate proteoglycan present in the vessel wall has been shown to inhibit SMC activity in vitro, and decrease intimal hyperplasia in animal models of arterial injury. As well, heparinase treatment of perlecan results in a loss of these inhibitory effects in vitro. This study examined the hypothesis that heparan sulfate (HS) has an inhibitory role in perlecan’s regulation of SMC activity. Aortic SMC from transgenic mice expressing HS-deficient Perlecan (M Δ3/Δ3 ) and control (WT) mice were isolated and cultured to characterize SMC activity. Additionally, M Δ3/Δ3 and control mice underwent a carotid artery wire injury and carotid arteries were harvested 1 week (n=6) and 3 weeks (n=12) post-surgery for histological analysis. Over 7 days, M Δ3/Δ3 cells showed significantly higher proliferation during the log phase (days 2–4), with almost a 2-fold increase in cell density during the plateau phase (days 5–7), compared to WT SMC (p&lt;0.001). Incubation with FGF-2 or PDGF-BB resulted in significantly greater M Δ3/Δ3 cell density versus WT (p&lt;0.001). PDGF-BB induced migration was also significantly greater in the M Δ3/Δ3 cells (216.2 ± 2.81) than the WT cells (151.9 ± 2.97) (p&lt;0.01). Following arterial injury, significant medial thickening was seen at 1 and 3 weeks, in WT and M Δ3/Δ3 arteries. Increases in medial thickness of M Δ3/Δ3 arteries were significantly greater than those seen in WT arteries at all respective time points (p&lt;0.001). In conclusion, the differences seen in SMC activity and response to arterial injury between WT and M Δ3/Δ3 populations demonstrate that the HS side chains play a critical role in perlecan’s inhibitory effects of SMC activity, and may indicate a promising therapeutic target for the prevention of restenosis following PCI.
Abstract 10732: BAY 94-8862 Exerts a Potent Natriuretic Effect in Healthy Male Subjects Pre-treated With Fludrocortisone: Findings From a Proof-of-concept Study
Authors: Silvia Lentini, Nina Kimmeskamp-Kirschbaum, Georg Wensing, Roland Heinig
Journal: Circulation (2012)

Background Activation of the mineralocorticoid receptor (MR) by aldosterone is known to promote the retention of sodium by the kidney and has an important role in the pathophysiology of heart failu...